- Home
- RUN vs KNSA Comparison
RUN vs KNSA Comparison
Compare RUN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUN | KNSA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RUN | KNSA |
|---|---|---|
| Price | $13.04 | $54.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 7 |
| Target Price | $18.80 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 7.7M | 795.8K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 113.35 | ★ 225.00 |
| EPS | ★ 1.71 | 0.27 |
| Revenue | ★ $858,578,000.00 | $677,564,000.00 |
| Revenue This Year | $2.81 | $37.48 |
| Revenue Next Year | $4.54 | $17.87 |
| P/E Ratio | ★ $7.44 | $198.13 |
| Revenue Growth | 12.97 | ★ 60.09 |
| 52 Week Low | $5.38 | $25.71 |
| 52 Week High | $22.44 | $54.31 |
Technical Indicators
Market Signals| Indicator | RUN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 71.26 |
| Support Level | $11.90 | $40.67 |
| Resistance Level | $13.57 | N/A |
| Average True Range (ATR) | 0.69 | 2.27 |
| MACD | 0.11 | 1.15 |
| Stochastic Oscillator | 85.24 | 96.82 |
Price Performance
Historical ComparisonAbout RUN Sunrun Inc.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.